1 Growth Stock Down 19% to Buy Right Now

Dexcom posted strong underlying performance despite a Class 1 recall of 602,445 G7 receivers, with Q3 revenue up 22% year-over-year to $1.2 billion and adjusted EPS rising 35.6% to $0.61. The company exited 2024 with roughly 2.8–2.9 million customers, reported only 112 complaints related to the issue as of June, and cites an addressable market of ~4.5 million insulin users not yet on CGM plus expanded demand from Stelo OTC approval—factors that support a sizable growth runway even as shares trade ~19% below their year-ago peak.

Analysis

Market structure: The recall is a near-term reputational hit but not a demand shock — DXCM grew revenue +22% YoY and ended 2024 with ~2.8–2.9M users while an estimated 4.5M insulin users remain addressable in the U.S., implying demand > supply for years. Winners include DXCM (long-term share gain via superior accuracy and OTC Stelo), payers that negotiate pricing leverage, and app/integration partners; losers are smaller OEMs with weak QC and any incumbent relying on receiver hardware. Options IV is likely elevated near events; corporate credit markets are largely unaffected but small-cap medtech peers could see spread widening of ~25–75bp on heightened recall risk.

Risk assessment: Tail risks include a broader systemic failure or mass litigation that forces extended replacements (could reduce free cash flow by 10–25% over 12–24 months) and payer reimbursement freezes that stall adoption. Immediate (days) risk is volatility and repricing; short-term (weeks–months) risk is weaker guidance or increased warranty/recall costs; long-term (3–5 years) upside hinges on Stelo adoption and payer expansion. Hidden dependencies: integration with insulin pumps, smartphone OS changes, and supplier QC; catalysts to watch are FDA/recall updates, quarterly customer trends, and major payer coverage decisions.

Trade implications: For patient capital, establish a 2–3% portfolio long in DXCM with a 12–36 month horizon, scaling in on any 8–20% pullback within the next 6–12 weeks. Hedged option play: buy Jan 2027 DXCM $65 LEAP call and sell Jan 2027 $85 call (1:1) to cap cost; tactical traders should buy 30–60 day 5% OTM puts ahead of earnings or use a short-term straddle if expecting >15% move. Consider a pair trade long DXCM / short ABT (ratio 1:0.6) to express device-share recovery vs incumbent pricing pressure.

Contrarian angle: Consensus overweights recall severity and underweights the new OTC TAM via Stelo — if Stelo captures even 10–20% of the 4.5M non-CGM insulin population over 3 years, DXCM revenue could compound well above current street estimates. But the market may be underpricing regulatory/friction costs: stronger QC and payer scrutiny could raise COGS and compress gross margin by 100–200bps. Historical recalls (MedTech peers) show 6–12 month troughs and multi-year recoveries; set exit rules tied to 4-quarter user growth and margin trends rather than headline noise.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in DXCM for a 12–36 month horizon, scaling in on any 8–20% pullback within the next 6–12 weeks; target hold unless quarterly active-user growth lags by >10% YoY or guidance is cut >10%.
• Implement a hedged LEAP: buy DXCM Jan 2027 $65 call and sell Jan 2027 $85 call (1:1) to express multi-year upside while limiting net cost; close or roll if DXCM rises >40% or falls >25% from entry.
• For tactical event-driven protection, buy 30–60 day DXCM 5% OTM puts ahead of the next earnings/FDA update window (expected within 4–8 weeks) or run a short-term straddle if anticipating >15% move; size at 0.5–1% portfolio risk.
• Enter a relative-value pair: long DXCM (1.5% portfolio) / short ABT (0.9% portfolio) for 12 months to express share recovery; unwind if DXCM market share does not improve after four consecutive quarters or if ABT outperforms DXCM by >15% over 90 days.
• Monitor three triggers closely: (a) FDA/recall technical bulletin within 30 days, (b) quarterly Stelo revenue and active-user growth over next 90 days, and (c) major payer coverage changes — if any trigger is negative and causes a >15% DXCM share drop in 30 days, reduce net long to 0.5%.